|
A
t Intrexon, we are changing the trajectory of molecular biology. No longer is it an artisanal process, where single-use design is the norm, and the risk of failure high. No longer are issues of cost and time an insurmountable barrier to realizing bold objectives. No longer do great ideas need to languish in a corner of the lab.
Intrexon’s technology portfolio is designed to create Better DNA™ at a truly industrial scale—thousands of gene programs and systems in the time that it takes traditional approaches to produce only one. Collectively, these capabilities deliver the full range of synthetic biology applications:
|
UltraVector® platform provides technology for the design and development of a diverse spectrum of biological components, accumulated and annotated for over a decade; thus creating a new and ever-advancing information tool set in the field of synthetic biology. The UltraVector® platform propels the development of life science products from genetic therapies to highly efficient recombinant organisms for manufacturing proteins and chemicals.
DNA and RNA MOD Engineering enabling rapid development promotors, chromatin modifiers, bioactive RNA species, and RNA motifs to regulate stability or control translation initiation.
Protein Engineering for enhanced or novel biofunctionalities such as novel enzyme inhibitors, localization signals, and fusion proteins with multivariate functionality.
Transcriptional Control Chemistry powering monogenic and multigenic systems inducible through a comprehensive library of activator ligands.
Genome Engineering featuring stable, location-based integration that doesn't disrupt critical cellular functions.
Cell System Engineering enabling controlled expression of individual traits or entire biosynthetic pathways, with subcellular positioning and enzyme control.
Combined with an advanced, rapid design-build-test framework, the outcome is Better DNA™ —DNA that produces the exacting results you desire at a molecular and cellular level. Intrexon’s core technology is a means to rationally engineer biological applications at an unprecedented scale. To our partners, however, it is simply a means to redefine what is possible.
|